The Asbestosis Treatment Market: How Industrial Asbestos Use Created a Global Healthcare Legacy
Asbestos was once called the “miracle mineral” — cheap, fire-resistant, and woven into the fabric of 20th-century industry. Decades later, the diseases it caused have generated a vast and growing asbestosis treatment market that continues to expand as the long tail of historical exposure works its way through global populations.
Understanding how this market emerged, what drives it, and what it means for the UK today requires looking honestly at the economic and human consequences of one of the most damaging industrial legacies in history.
Why Asbestos-Related Disease Created a Global Treatment Market
The asbestosis treatment market didn’t emerge overnight. It is the direct product of decades of industrial asbestos use, combined with the mineral’s uniquely cruel latency period — typically 20 to 50 years between first exposure and disease onset.
Workers who inhaled asbestos fibres in shipyards, construction sites, power stations, and factories during the 1960s, 1970s, and 1980s are only now, in many cases, receiving diagnoses. This means that even though asbestos use in the UK was banned in 1999, the healthcare burden from that use is still building — not declining.
Three primary conditions drive demand within the asbestosis treatment market:
- Asbestosis — a chronic, progressive fibrosis of the lung tissue caused by prolonged asbestos inhalation
- Mesothelioma — an aggressive cancer of the lung lining or abdominal cavity, almost exclusively caused by asbestos exposure
- Asbestos-related lung cancer — where asbestos exposure is a contributing or primary cause
Each of these conditions requires ongoing medical management, specialist intervention, and in many cases, long-term palliative care. Together, they represent a substantial and sustained demand on healthcare systems worldwide.
What Drives Growth in the Asbestosis Treatment Market
Several structural factors continue to drive the expansion of the asbestosis treatment market, both in the UK and globally. These aren’t short-term pressures — they are baked into the epidemiology of asbestos-related disease and will persist for decades.
The Latency Effect
Because asbestosis and related diseases take decades to manifest, the peak of diagnoses in many countries lags significantly behind the peak of asbestos use. In the UK, mesothelioma diagnoses were expected to reach their highest point in the early 2020s before beginning a gradual decline.
That decline, however, will be slow — and the treatment burden will persist for many years beyond it. The latency effect means the asbestosis treatment market has a built-in forward momentum that no policy change can quickly reverse.
Continued Exposure in Developing Markets
While the UK, European Union, Australia, and many other developed nations have banned asbestos, significant volumes of chrysotile asbestos continue to be mined and exported — primarily from Russia and Kazakhstan — to markets in South and Southeast Asia.
Countries including India, Indonesia, and parts of Africa continue to use asbestos in construction and manufacturing. This means the global asbestosis treatment market will continue to grow in these regions for decades to come, as current exposures translate into future diagnoses.
Advances in Medical Treatment
Investment in oncology and respiratory medicine has produced new treatment options for asbestos-related diseases. Immunotherapy, in particular, has shown meaningful results in extending survival for some mesothelioma patients — a disease that was previously considered almost universally fatal within months of diagnosis.
These advances have expanded the asbestosis treatment market by increasing the duration and complexity of care pathways. Patients who previously had limited treatment options now undergo extended courses of therapy, increasing both the clinical and commercial activity within the market.
Compensation and Litigation Activity
The asbestosis treatment market is closely linked to the legal and compensation landscape. In the UK, employer liability claims and compensation schemes for asbestos-related disease represent a continuing financial flow.
In the United States, asbestos compensation trust funds — established by bankrupt manufacturers — hold billions of dollars specifically to pay out to future claimants. This compensation activity funds treatment, supports affected families, and sustains specialist legal and medical services that form part of the broader asbestosis treatment ecosystem.
The Economic Collapse of the Asbestos Industry
To understand the asbestosis treatment market fully, it helps to understand the economic history that created it. The global asbestos industry didn’t collapse through commercial failure — it was deliberately dismantled as the evidence of harm became impossible to ignore.
Regulatory bans rolled out across the developed world from the 1980s onwards:
- Iceland introduced the first comprehensive national ban in 1983
- Norway followed with strict restrictions in 1984
- Denmark and Sweden enacted general prohibitions in 1986
- The European Union mandated a full ban across member states in 1999
- The UK banned all forms of asbestos, including chrysotile, in 1999
- Australia introduced a nationwide prohibition in 2003
- Japan prohibited manufacture, import, and use in 2004
- Canada enacted regulations prohibiting import, sale, and use in 2018
Each of these bans closed a chapter of industrial use — but opened a much longer chapter of health consequences and treatment demand.
Job Losses and Community Devastation
For producing nations, the bans didn’t just end an industry — they hollowed out communities that had been built around asbestos mining. Canada’s experience is particularly stark. The Thetford Mines and Asbestos regions of Quebec had been producing chrysotile since the late 19th century, and when the last Canadian asbestos mine closed in 2011, it ended over a century of industrial activity.
Similar patterns emerged in South Africa, where asbestos mining had centred on the Northern Cape and Limpopo provinces, and in parts of southern Europe where quarrying operations had sustained small regional economies. Retraining programmes helped, but the transition was slow — alternative employers simply didn’t exist in many of these communities.
The Rise of Substitute Materials
The withdrawal of asbestos from construction, manufacturing, and industrial applications created immediate commercial demand for alternatives. This drove significant growth in several material categories:
- Mineral wool and glass wool — for building insulation
- Cellulose fibre — as a replacement in board and panel products
- Aramid fibres — used in automotive braking systems
- Ceramic composites — for high-temperature industrial applications
- Calcium silicate and fibre-reinforced cement — in construction and fireproofing
Companies that invested early in developing viable substitutes were well-positioned to capture this demand. The asbestos ban, in effect, created a significant commercial opportunity for an entirely new generation of materials manufacturers.
The UK’s Ongoing Asbestosis Treatment Burden
The UK used asbestos extensively across shipbuilding, construction, power generation, and manufacturing. The scale of that use means the domestic asbestosis treatment market remains substantial, with NHS treatment costs, specialist oncology services, and compensation schemes all representing ongoing financial commitments.
Mesothelioma alone — the cancer most directly associated with asbestos — continues to account for several thousand new diagnoses per year in the UK. Each diagnosis typically involves a complex care pathway including surgery assessment, chemotherapy, immunotherapy, and palliative care.
The NHS and private healthcare providers together sustain a significant infrastructure to manage this demand. That infrastructure — the specialist centres, the clinical trials, the palliative care networks — represents the human and financial cost of a century of industrial asbestos use playing out in real time.
The Public Health Economics of the Asbestos Ban
Set against the economic disruption of banning asbestos, the long-term public health savings are substantial. Fewer people exposed means fewer people developing asbestosis, mesothelioma, and asbestos-related lung cancer — diseases that are expensive to treat, frequently fatal, and impose enormous costs on healthcare systems, families, and social care services.
The economic logic of prohibition is straightforward: the short-term disruption of removing an industrial material is substantially outweighed by the long-term reduction in healthcare expenditure, lost productivity, and human suffering. This calculation underpins health policy in every country that has enacted a ban.
It also makes the case for rigorous asbestos management in buildings that still contain the material — because every new exposure today is a potential diagnosis in 20 or 30 years’ time, adding further demand to an already stretched asbestosis treatment market.
Asbestos Still in UK Buildings: The Ongoing Exposure Risk
The asbestosis treatment market exists because exposure happened. Preventing future exposure — and therefore preventing future demand on that market — depends on managing the asbestos that remains in place across the UK’s existing building stock.
Any non-domestic building constructed or refurbished before 2000 may contain asbestos-containing materials (ACMs). This includes offices, schools, hospitals, industrial premises, and public buildings. The material was used in insulation boards, ceiling tiles, floor tiles, roofing sheets, pipe lagging, and fire protection systems — it is present in a significant proportion of the UK’s commercial and public building stock.
Under the Control of Asbestos Regulations, dutyholders have a legal obligation to identify, assess, and manage any asbestos present in their premises. This isn’t a discretionary responsibility — it carries real legal and financial consequences if ignored.
What Dutyholders Must Do
The practical steps for compliance are clear. A management survey is the starting point for any dutyholder seeking to understand what asbestos-containing materials are present in their building and what condition they’re in.
Beyond commissioning that initial survey, dutyholders should:
- Assess the risk posed by each identified material based on its condition and likelihood of disturbance
- Produce and maintain an asbestos register recording all findings
- Implement a management plan setting out how ACMs will be monitored or remediated
- Ensure any contractors working in the building are informed of asbestos locations before work begins
- Review the register and management plan regularly, particularly after any building works
Failure to follow these steps exposes dutyholders to HSE enforcement action, improvement notices, and potential prosecution. It also creates significant liability risk if workers or occupants are subsequently found to have been exposed.
Where Asbestos Surveys Are Most Urgently Needed
Across the UK, the concentration of older commercial and industrial buildings means that asbestos survey demand is particularly high in major urban centres. If you manage property in any of these areas, professional survey provision is readily available.
In the capital, our asbestos survey London service covers commercial, residential, and public sector properties across all London boroughs, with rapid turnaround and full compliance reporting.
In the North West, our asbestos survey Manchester team works across Greater Manchester’s extensive stock of industrial and commercial premises — many of which date from periods of peak asbestos use.
In the Midlands, our asbestos survey Birmingham service supports property managers, local authorities, and businesses across the region with fully accredited surveys conducted to HSG264 standards.
The Global Asbestosis Treatment Market: What Comes Next
Looking forward, the trajectory of the asbestosis treatment market will be shaped by two competing forces. In countries that banned asbestos early — the UK, much of Europe, Australia — the market will gradually contract as the cohort of heavily exposed workers ages and, ultimately, reduces in size.
But that contraction will be slow. The latency of asbestos-related disease means that the treatment and compensation infrastructure built up over recent decades will remain necessary well into the second half of this century. Specialist mesothelioma centres, asbestos-related disease clinics, and compensation legal services will all continue to operate at significant scale for years to come.
In developing nations where asbestos use continues, the trajectory runs in the opposite direction entirely. Growing construction sectors, continued asbestos imports, and limited occupational health regulation mean that the asbestosis treatment market in South and Southeast Asia, and parts of Africa, is still in its early growth phase. The diagnoses that will flow from current exposures in these regions won’t begin to peak for decades.
Globally, the asbestosis treatment market is therefore not a declining sector — it is a market in transition, contracting in some geographies while expanding sharply in others. The total burden of asbestos-related disease worldwide remains substantial and will do so for the foreseeable future.
The Role of Innovation in Treatment
Medical research continues to shift the outlook for patients diagnosed with asbestos-related diseases. Combination immunotherapy regimens have improved survival outcomes for certain mesothelioma patients, and clinical trials continue to explore targeted therapies that could further extend prognosis.
These developments are welcome — but they also mean that each patient diagnosed today is likely to require a longer, more complex, and more expensive course of treatment than a patient diagnosed a decade ago. This dynamic sustains the economic scale of the asbestosis treatment market even as the number of new diagnoses in some countries begins to plateau.
Prevention Remains the Only Long-Term Solution
No treatment advance changes the fundamental reality: asbestos-related diseases are entirely preventable. Every case of asbestosis, mesothelioma, or asbestos-related lung cancer that enters the treatment market is the result of an exposure that, with proper management, need not have occurred.
In the UK, where the asbestos ban has been in place for over two decades, the focus must be on managing the material that remains in the existing building stock. Dutyholders who take their obligations under the Control of Asbestos Regulations seriously — commissioning proper surveys, maintaining accurate registers, and informing tradespeople before work begins — are directly contributing to the reduction of future diagnoses.
That is not an abstract public health benefit. It is a concrete reduction in human suffering, NHS expenditure, and the ongoing social cost of a century of industrial asbestos use.
Frequently Asked Questions
What is the asbestosis treatment market?
The asbestosis treatment market refers to the healthcare, pharmaceutical, and medical services sector that has developed in response to the widespread incidence of asbestos-related diseases — including asbestosis, mesothelioma, and asbestos-related lung cancer. It encompasses specialist oncology services, respiratory medicine, palliative care, clinical trials, and associated compensation and legal services.
Why is the asbestosis treatment market still growing if asbestos is banned in the UK?
Asbestos-related diseases have a latency period of typically 20 to 50 years between exposure and diagnosis. Workers exposed during the peak decades of UK asbestos use — the 1960s, 1970s, and 1980s — are still receiving diagnoses today. The ban prevents future exposure but cannot reverse the health consequences of past use, which is why treatment demand remains high and will do so for many years.
What legal obligations do UK property managers have regarding asbestos?
Under the Control of Asbestos Regulations, dutyholders responsible for non-domestic premises built or refurbished before 2000 must identify any asbestos-containing materials present, assess the risk they pose, maintain an asbestos register, and implement a management plan. Commissioning a professional management survey is the standard starting point for meeting these obligations.
Does asbestos in buildings still pose a risk today?
Yes. Asbestos-containing materials that are in poor condition, or that are disturbed during maintenance or refurbishment work, can release respirable fibres. This is why the Control of Asbestos Regulations place a duty of management on building owners and managers — undisturbed, well-managed asbestos may be safe to leave in place, but it must be identified and monitored to ensure that remains the case.
How do I arrange an asbestos survey for my building?
Contact a UKAS-accredited asbestos surveying company to arrange a management survey or, where refurbishment or demolition work is planned, a refurbishment and demolition survey. Supernova Asbestos Surveys operates nationwide and provides fully accredited surveys conducted to HSG264 standards. Call us on 020 4586 0680 or visit asbestos-surveys.org.uk to arrange a survey for your property.
Speak to Supernova Asbestos Surveys
Supernova Asbestos Surveys has completed over 50,000 surveys nationwide, helping property managers, local authorities, and businesses meet their legal obligations under the Control of Asbestos Regulations. Whether you manage a single commercial unit or a large estate portfolio, our accredited surveyors provide clear, actionable reports that give you the information you need to manage asbestos safely and compliantly.
Call us on 020 4586 0680 or visit asbestos-surveys.org.uk to book your survey or discuss your requirements with our team.

































